| Literature DB >> 34069498 |
Mario Díaz1,2, Fernando Lobo3, Dácil Hernández4, Ángel Amesty3,5, Catalina Valdés-Baizabal3,6, Ana Canerina-Amaro6, Fátima Mesa-Herrera1, Kevin Soler7, Alicia Boto2,4, Raquel Marín2,6, Ana Estévez-Braun5,8, Fernando Lahoz2,7.
Abstract
Tamoxifen is the most widely used selective modulator of estrogen receptors (SERM) and the first strategy as coadjuvant therapy for the treatment of estrogen-receptor (ER) positive breast cancer worldwide. In spite of such success, tamoxifen is not devoid of undesirable effects, the most life-threatening reported so far affecting uterine tissues. Indeed, tamoxifen treatment is discouraged in women under risk of uterine cancers. Recent molecular design efforts have endeavoured the development of tamoxifen derivatives with antiestrogen properties but lacking agonistic uterine tropism. One of this is FLTX2, formed by the covalent binding of tamoxifen as ER binding core, 7-nitrobenzofurazan (NBD) as the florescent dye, and Rose Bengal (RB) as source for reactive oxygen species. Our analyses demonstrate (1) FLTX2 is endowed with similar antiestrogen potency as tamoxifen and its predecessor FLTX1, (2) shows a strong absorption in the blue spectral range, associated to the NBD moiety, which efficiently transfers the excitation energy to RB through intramolecular FRET mechanism, (3) generates superoxide anions in a concentration- and irradiation time-dependent process, and (4) Induces concentration- and time-dependent MCF7 apoptotic cell death. These properties make FLTX2 a very promising candidate to lead a novel generation of SERMs with the endogenous capacity to promote breast tumour cell death in situ by photosensitization.Entities:
Keywords: FLTX1; FRET; SERM; breast cancer; estrogen receptors; fluorescence; laser dye; molecular dynamics; photosensitization; reactive oxygen species; superoxide anions; tamoxifen
Year: 2021 PMID: 34069498 PMCID: PMC8161337 DOI: 10.3390/ijms22105339
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1(A) Synthesis of FLTX2 (compound 3). (B) Minimized 3D representation of FLTX2 (3) highlighting the sequence: excitation wavelength, intramolecular FRET, red emission, and singlet oxygen generation. For details see optical measurements DIPEA: Diisopropylethylamine; DMAP: Dimethylaminopyridine; DMF: Dimethylformamide; HBTU: O-(Benzotriazol-1-yl)- N,N,N′,N′-tetramethyluronium hexafluorophosphate; NBD: 7-nitrobenzofurazan; THF: tetrahydrofuran.
Figure 2Effects of FLTX2 and TX on [3H]-estradiol competitive ER binding assay. Uterine cytosolic extracts were saturated with 5 nM of labelled estradiol in the presence of increasing concentrations of unlabelled estradiol (E2), tamoxifen (TX), or FLTX2. Data are presented as mean ± SEM of four different assays.
Figure 3Best Docking poses for TX (A), FLTX1 (B), and FLTX2 (C) in the human ERα ligand binding domains (LBD). (D) Overlapped docking poses of TX and FLTX2 within the human ERα LBD.
Figure 4Molecular Dynamics study for FLTX2 on the human ERα ligand binding domain. (A) Interactions of FLTX2 with key amino acid residues at the hydrophobic binding pocket of human ERα LBD. (B) 2D Ligand-protein interaction diagrams and interaction strength quantified by the frequency of occurrences in the trajectory when a minimum percentage of 50% is achieved. Colors indicate type of residue: green are lipophilic residues; blue are polar residues; purple are basic residues. Ligand atoms that are exposed to the solvent are marked with grey spheres. (C) Stacked bar charts of human ERα LBD interaction with FLTX2.
Figure 5Optical properties of FLTX2. (A) Absorption spectra of FLTX1, RB, and FLTX2. (B) Normalized emission spectra of FLTX1, RB, and FLTX2. (C) Decay of the fluorescence of RB and of FLTX2 with detection tuned at 608 nm. (D) Decay of the fluorescence of FLTX1 and of FLTX2 with detection tuned at 550 nm.
Figure 6FLTX2-induced ROS generation. (A) Superoxide anion-induced formation of nitro blue tetrazolium-formazan. (B) Absorption spectra of equimolar FLTX2 and RB solutions after laser irradiation for 10 min. (C) Concentration-dependence of FLTX2-induced formazan formation irradiated for 2 or 10 min. (D) Time-dependence for FLTX2-induced (50 µM) formazan generation.
Figure 7Cellular labeling of FLTX2 and occurrence of FRET in MCF-7 cells. (A) Representative images of irradiated preparations (450 nm, 30 min) incubated with different concentrations of FLTX2 (0, 50, and 100 μM). Fluorescent signals were recorded at the emission band of RB (600 nm). DAPI was used as nuclear marker. (B) Concentration-dependent fluorescent signals in cytoplasmic and nuclear compartments. (C) Demonstration of FRET efficiency in FLTX2 irradiation. Fluorescent signal was virtually absent at the emission wavelength of the NBD moiety of FLTX1. (D) bar chart comparing fluorescence signals recorded at 530 nm (NBD moiety) and 600 nm (NBD to RB transfer). *** Statistically significant at p < 0.005.
Figure 8Photodynamic effects of FLTX2. (A) Effects of laser irradiation (475 nm) for 30 min on MCF-7 cells viability. (B) Concentration-dependence effects on MCF-7 cells viability irradiated for 30 min. (C) Effects of irradiation time on FLTX2-induced toxicity. (D) Phase contrast transmission representative images of irradiated and non-irradiated MCF-7 cells at different concentrations of FLTX2. Arrows indicate different apoptotic traits: intracellular vacuolation (black arrows), membrane blebbing (blue arrows), cell shrinkage (red arrows), cellular fragmentation (green arrows).